Table 2.
Paternal SSRI use before conception | Offspring with ASD, n | Follow-up number of person-years | HR (95% CI) | ||
Crude | Model 1* | Model 2† | |||
No use during the last 3 months prior to conception | 7473 | 6 765 205 | Ref | Ref | Ref |
Use during the last 3 months prior to conception | 104 | 61 555 | 1.62 (1.33 to 1.96) | 1.54 (1.27 to 1.88) | 1.43 (1.18 to 1.74) |
Subanalysis: paternal SSRI use during the last 1 year before conception | |||||
No use during the last 1 year prior to conception | 7429 | 6 736 654 | Ref | Ref | Ref |
Use only from the last 1 year to the last 3 months prior to conception | 71 | 39 422 | 1.71 (1.35 to 2.16) | 1.66 (1.31 to 2.09) | 1.54 (1.21 to 1.94) |
Use only during the last 3 months prior to conception | 20 | 14 738 | 1.29 (0.83 to 2.00) | 1.24 (0.80 to 1.93) | 1.17 (0.75 to 1.82) |
Use both before and during the last 3 months prior to conception | 57 | 35 946 | 1.52 (1.17 to 1.97) | 1.43 (1.10 to 1.86) | 1.32 (1.02 to 1.72) |
*Adjusted for calendar year of birth, sex, parity, mother age, father age, maternal smoking, mother psychiatric history, maternal AD use during pregnancy.
†Model 1 further adjusted for father psychiatric history.
AD, antidepressant drug; ASD, autism spectrum disorder; n, number; SSRI, selective serotonin reuptake inhibitor.